Werewolf Therapeutics (NASDAQ:HOWL) Director Sells $31,936.50 in Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 67,950 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $0.47, for a total transaction of $31,936.50. Following the sale, the director directly owned 763,685 shares in the company, valued at $358,931.95. The trade was a 8.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $39,341.25.
• On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.42, for a total transaction of $15,282.54.
• On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.43, for a total transaction of $36,934.85.
• On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.45, for a total transaction of $28,336.50.
• On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.50, for a total transaction of $11,092.00.
• On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total transaction of $43,446.40.
• On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.67, for a total transaction of $22,745.16.
• On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.70, for a total transaction of $214,018.70.
• On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $49,824.18.
• On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.66, for a total transaction of $9,659.10.

Werewolf Therapeutics Price Performance

Shares of HOWL stock opened at $0.46 on Friday. The company’s fifty day simple moving average is $0.75 and its two-hundred day simple moving average is $0.75. Werewolf Therapeutics, Inc. has a 1 year low of $0.40 and a 1 year high of $2.38. The stock has a market capitalization of $22.16 million, a price-to-earnings ratio of -0.37 and a beta of 0.41.

Werewolf Therapeutics (NASDAQ:HOWL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.04. Equities research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Regal Investment Advisors LLC increased its holdings in shares of Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock worth $33,000 after purchasing an additional 25,389 shares during the period. Vontobel Holding Ltd. grew its position in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after acquiring an additional 24,003 shares in the last quarter. Renaissance Technologies LLC grew its position in Werewolf Therapeutics by 48.6% in the fourth quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after acquiring an additional 221,766 shares in the last quarter. Susquehanna International Group LLP grew its position in Werewolf Therapeutics by 16.9% in the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after acquiring an additional 13,439 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Werewolf Therapeutics in the third quarter worth $304,000. Institutional investors own 64.84% of the company’s stock.

Wall Street Analyst Weigh In

HOWL has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Wall Street Zen cut shares of Werewolf Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $3.75.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.